Involvement of ERK-RSK cascade in phenylephrine-induced phosphorylation of GATA4

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 2, 2012, Pages 582-592

  Li, Tao ^a   Liu, Zhiqiang ^c   Hu, Xiaoqing ^b   Ma, Kangtao ^b   Zhou, Chunyan ^b  

^a ZHEJIANG NORMAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cardiac hypertrophy; ERK; GATA4; Phosphorylation; RSK

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHENYLEPHRINE; PROTEIN P300; S6 KINASE; SERINE; TRANSCRIPTION FACTOR GATA 4;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA BINDING; GENE; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; TRANSCRIPTION REGULATION;

ANIMALS; ANIMALS, NEWBORN; CARDIOTONIC AGENTS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GATA4 TRANSCRIPTION FACTOR; HYPERTROPHY; MYOCYTES, CARDIAC; PHENYLEPHRINE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION;

ADENOVIRIDAE;

EID: 84862822434     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.12.009     Document Type: Article

References (47)

1. Oka T., Xu J., Molkentin J.D. Re-employment of developmental transcription factors in adult heart disease. Semin. Cell Dev. Biol. 2007, 18:117-131.
2. Suzuki Y.J. Cell signaling pathways for the regulation of GATA4 transcription factor: implications for cell growth and apoptosis. Cell. Signal. 2011, 23:1094-1099.
3. Kuo C.T., Morrisey E.E., Anandappa R., Sigrist K., Lu M.M., Parmacek M.S., Soudais C., Leiden J.M. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 1997, 11:1048-1060.
4. Molkentin J.D., Lin Q., Duncan S.A., Olson E.N. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 1997, 11:1061-1072.
5. Charron F., Tsimiklis G., Arcand M., Robitaille L., Liang Q., Molkentin J.D., Meloche S., Nemer M. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 2001, 15:2702-2719.
6. Liang Q., De Windt L.J., Witt S.A., Kimball T.R., Markham B.E., Molkentin J.D. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J. Biol. Chem. 2001, 276:30245-30253.
7. Kitta K., Day R.M., Kim Y., Torregroza I., Evans T., Suzuki Y.J. Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells. J. Biol. Chem. 2003, 278:4705-4712.
8. Kobayashi S., Lackey T., Huang Y., Bisping E., Pu W.T., Boxer L.M., Liang Q. Transcription factor gata4 regulates cardiac BCL2 gene expression in vitro and in vivo. FASEB J. 2006, 20:800-802.
9. Kobayashi S., Volden P., Timm D., Mao K., Xu X., Liang Q. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J. Biol. Chem. 2010, 285:793-804.
10. Suzuki Y.J., Nagase H., Wong C.M., Kumar S.V., Jain V., Park A.M., Day R.M. Regulation of Bcl-xL expression in lung vascular smooth muscle. Am. J. Respir. Cell Mol. Biol. 2007, 36:678-687.
11. Oka T., Maillet M., Watt A.J., Schwartz R.J., Aronow B.J., Duncan S.A., Molkentin J.D. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 2006, 98:837-845.
12. Shan X., Xu X., Cao B., Wang Y., Guo L., Zhu Q., Li J., Que L., Chen Q., Ha T., Li C., Li Y. Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury. Int. J. Cardiol. 2009, 134:384-392.
13. Suzuki Y.J., Nagase H., Day R.M., Das D.K. GATA-4 regulation of myocardial survival in the preconditioned heart. J. Mol. Cell. Cardiol. 2004, 37:1195-1203.
14. Kerkela R., Pikkarainen S., Majalahti-Palviainen T., Tokola H., Ruskoaho H. Distinct roles of mitogen-activated protein kinase pathways in GATA-4 transcription factor-mediated regulation of B-type natriuretic peptide gene. J. Biol. Chem. 2002, 277:13752-13760.
15. Liang Q., Wiese R.J., Bueno O.F., Dai Y.S., Markham B.E., Molkentin J.D. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol. Cell. Biol. 2001, 21:7460-7469.
16. Tenhunen O., Sarman B., Kerkela R., Szokodi I., Papp L., Toth M., Ruskoaho H. Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J. Biol. Chem. 2004, 279:24852-24860.
17. Yanazume T., Hasegawa K., Wada H., Morimoto T., Abe M., Kawamura T., Sasayama S. Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J. Biol. Chem. 2002, 277:8618-8625.
18. Chandrasekar B., Mummidi S., Claycomb W.C., Mestril R., Nemer M. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J. Biol. Chem. 2005, 280:4553-4567.
19. Morisco C., Seta K., Hardt S.E., Lee Y., Vatner S.F., Sadoshima J. Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J. Biol. Chem. 2001, 276:28586-28597.
20. Dai Y.S., Cserjesi P., Markham B.E., Molkentin J.D. The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J. Biol. Chem. 2002, 277:24390-24398.
21. Dai Y.S., Markham B.E. p300 Functions as a coactivator of transcription factor GATA-4. J. Biol. Chem. 2001, 276:37178-37185.
22. Durocher D., Charron F., Warren R., Schwartz R.J., Nemer M. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. EMBO J. 1997, 16:5687-5696.
23. Tremblay J.J., Viger R.S. Transcription factor GATA-4 is activated by phosphorylation of serine 261 via the cAMP/protein kinase a signaling pathway in gonadal cells. J. Biol. Chem. 2003, 278:22128-22135.
24. Anjum R., Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 2008, 9:747-758.
25. Hauge C., Frodin M. RSK and MSK in MAP kinase signalling. J. Cell Sci. 2006, 119:3021-3023.
26. Vermeulen L., Vanden Berghe W., Beck I.M., De Bosscher K., Haegeman G. The versatile role of MSKs in transcriptional regulation. Trends Biochem. Sci. 2009, 34:311-318.
27. Zeniou M., Ding T., Trivier E., Hanauer A. Expression analysis of RSK gene family members: the RSK2 gene, mutated in Coffin-Lowry syndrome, is prominently expressed in brain structures essential for cognitive function and learning. Hum. Mol. Genet. 2002, 11:2929-2940.
28. Baliga R.R., Pimental D.R., Zhao Y.Y., Simmons W.W., Marchionni M.A., Sawyer D.B., Kelly R.A. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am. J. Physiol. 1999, 277:H2026-H2037.
29. He Q., Harding P., LaPointe M.C. PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H136-H143.
30. Markou T., Cieslak D., Gaitanaki C., Lazou A. Differential roles of MAPKs and MSK1 signalling pathways in the regulation of c-Jun during phenylephrine-induced cardiac myocyte hypertrophy. Mol. Cell. Biochem. 2009, 322:103-112.
31. Markou T., Hadzopoulou-Cladaras M., Lazou A. Phenylephrine induces activation of CREB in adult rat cardiac myocytes through MSK1 and PKA signaling pathways. J. Mol. Cell. Cardiol. 2004, 37:1001-1011.
32. Sadoshima J., Qiu Z., Morgan J.P., Izumo S. Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. The critical role of Ca(2+)-dependent signaling. Circ. Res. 1995, 76:1-15.
33. Takeishi Y., Huang Q., Abe J., Glassman M., Che W., Lee J.D., Kawakatsu H., Lawrence E.G., Hoit B.D., Berk B.C., Walsh R.A. Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. J. Mol. Cell. Cardiol. 2001, 33:1637-1648.
34. Zhang C.G., Jia Z.Q., Li B.H., Zhang H., Liu Y.N., Chen P., Ma K.T., Zhou C.Y. beta-Catenin/TCF/LEF1 can directly regulate phenylephrine-induced cell hypertrophy and Anf transcription in cardiomyocytes. Biochem. Biophys. Res. Commun. 2009, 390:258-262.
35. Massin M.M., Radermecker M.A., Verloes A., Jacquot S., Grenade T. Cardiac involvement in Coffin-Lowry syndrome. Acta Paediatr. 1999, 88:468-470.
36. Wu M., Hemesath T.J., Takemoto C.M., Horstmann M.A., Wells A.G., Price E.R., Fisher D.Z., Fisher D.E. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000, 14:301-312.
37. Sutherland C., Leighton I.A., Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 1993, 296(Pt 1):15-19.
38. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13489-13494.
39. Shahbazian D., Roux P.P., Mieulet V., Cohen M.S., Raught B., Taunton J., Hershey J.W., Blenis J., Pende M., Sonenberg N. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006, 25:2781-2791.
40. Cuello F., Bardswell S.C., Haworth R.S., Ehler E., Sadayappan S., Kentish J.C., Avkiran M. Novel role for p90 ribosomal S6 kinase in the regulation of cardiac myofilament phosphorylation. J. Biol. Chem. 2011, 286:5300-5310.
41. Itoh S., Ding B., Bains C.P., Wang N., Takeishi Y., Jalili T., King G.L., Walsh R.A., Yan C., Abe J. Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphorylation. J. Biol. Chem. 2005, 280:24135-24142.
42. Janknecht R. Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 2003, 22:746-755.
43. Kehat I., Molkentin J.D. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann. N. Y. Acad. Sci. 2010, 1188:96-102.
44. Lorenz K., Schmitt J.P., Vidal M., Lohse M.J. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int. J. Biochem. Cell Biol. 2009, 41:2351-2355.
45. Muslin A.J. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. (Lond.) 2008, 115:203-218.
46. Rohini A., Agrawal N., Koyani C.N., Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol. Res. 2010, 61:269-280.
47. Szokodi I., Kerkela R., Kubin A.M., Sarman B., Pikkarainen S., Konyi A., Horvath I.G., Papp L., Toth M., Skoumal R., Ruskoaho H. Functionally opposing roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the regulation of cardiac contractility. Circulation 2008, 118:1651-1658.